Myeloma Therapy

Biologic Consideration and Myeloma.- Staging in Multiple Myeloma.- Epidemiology of Multiple Myeloma.- Basic Biology of Plasma Cell Dyscrasias: Focus on the Role of the Tumor Microenviroment.- Biology-Based Classification and Staging of Multiple Myeloma.- Cytogenetic Abnormalities in Multiple Myeloma: The Importance of FISH and Cytogenetics.- Historical and Cytotoxic Agent-Based Therapies for Myeloma.- Role of Autologous Stem Cell Transplantation in Multiple Myeloma.- Maintenance Therapy in Multiple Myeloma.- Therapy for Patients not Eligible for Autologous Transplant.- Current Role of Anthracyclines in the Treatment of Multiple Myeloma.- Immune-Based Therapies.- Allogeneic Transplantation for Multiple Myeloma.- Immunobiology and Immunotherapy of Multiple Myeloma.- Antibody and Other Immune-Based Therapies for Myeloma.- Existing Novel Agents.- Thalidomide in Patients with Relapsed Multiple Myeloma.- Thalidomide: Induction Therapy.- The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma.- Bortezomib as Induction Therapy in Patients with Multiple Myeloma.- Lenalidomide in Relapsed or Refractory Multiple Myeloma.- Lenalidomide for Initial Therapy of Newly Diagnosed Multiple Myeloma.- Current and Future Targets.- The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma.- The PI3 Kinase/Akt Pathway as a Therapeutic Target in Multiple Myeloma.- The Mammalian Target of Rapamycin and Multiple Myeloma.- CDK Inhibitors in Multiple Myeloma.- Fibroblast Growth Factor Receptor 3 and Multiple Myeloma.- Histone Deacetylase Inhibitors in Multiple Myeloma.- Death Receptors in Multiple Myeloma and Therapeutic Opportunities.- Proteasome Inhibitors as Therapy in Multiple Myeloma.- Supportive Care.- Pathophysiology of Bone Disease in Multiple Myeloma.- Anemia and Erythropoeitic Growth Factors in Multiple Myeloma.- Percutaneous Vertebroplasty and Balloon Kyphoplasty for the Treatment of Acute Painful Pathologic and Nonpathologic Fractures.- The Role of Anatomic and Functional Imaging in Myeloma.- Management of Multiple Myeloma Patients with Renal Dysfunction.- Other Plasma Cell Disorders.- Waldenstrom's Macroglobulinemia.- AL (Immunoglobulin Light-Chain) Amyloidosis.- POEMS Syndrome and Other Atypical Plasma Cell Disorders.- Monoclonal Gammopathy of Undetermined Significance.

From the reviews:"The book Myeloma Therapy: Pursuing the Plasma Cell, edited by Sagar Lonial, arrives just in time. … a comprehensive, updated review of all the problems concerning myeloma. The authors are among the world’s top scientific leaders in this field … . Consultation and systematic reading are interesting, useful, and very agreeable. It cannot be lacking in the library of the hematologists and oncologists taking care of myeloma patients, and it’s also a worthwhile volume for scientists involved in preclinical research." (Sergio Storti, Laboratory Hematology, Vol. 15 (34), 2009)“Myeloma therapy by Sagar Lonial deals with various aspects of the plasma cell disorders and multiple myeloma in particular. … this is a goldmine of information written in a style that is accessible to the biochemically interested clinician. … is highly recommended to the advanced reader in this field. It is a reference work on both clinical and biological aspects of multiple myeloma and should be part of the libraries of hospitals for physicians who are professionally frequently involved with the treatment of this disease.” (F. Offner, Acta Clinica Belgica, Vol. 65 (3), 2010)